Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (443)	12/16/2003 4:43:18 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Well, it seems that ASTM did better than DNDN after their presentation at the "Informed Investors Biotech/Cancer Stocks Virtual Forum" this morning.<g> DNDN's CEO, Dr.Mitchell Gold provided an overview of its pipeline,including Provenge, which is on PIII for the treatment of androgen independent prostatic Ca.(According to latest reports, after 6 months, 36% of patients on Provenge were "progression free", compared with only 4% of controls.) DNDN had recently benefited from the comments on an article on the NY Times,in which it was mentioned that it had started trials for its cancer vaccines for ovarian, breast and colon Cas and that according to the company results so far had been promising. nytimes.com bigcharts.marketwatch.com bigcharts.marketwatch.com Bernard